Expression Of TRAIL Protein And MRNA In Body Surface Hemangioma

Objective: Hemangioma, the most common tumor of infancy and childhood,is characterized by endothelial proliferation histologically and by rapid uncontrolled growth clinically.Its development typically exhibits a proliferative phase followed by an involuting phase that continues into the involuted phase. The pathogenesis of Hemangioma has not yet been elucidated. The treatment of Hemangioma is not very ideal. Apoptosis or programmed cell death has been observed in the regressin of hemangioma.However,factors responsible for regulating apoptosis in hemangioma are not well defined. So we projected to carred out an immunohistochemial and in situ hybrization study of TNF related apoptosis inducing ligand(TRAIL)protein and mRNA in hemangioma,in an effort to understand the effect of TRAIL protein and mRNA during the hemangiogenesis and regression, offer a basic rational for clinical diagnosis and evaluating therapy result, and provid a new clinical therapy pathways.Methods: In this experiment,We analyzed TRAIL protein and mRNA expression of 33 proliferative hemangiomas,28 involutong hemangiomas , 29 vascular malformations, and 20 cases of control specimens ,which were harvested during excisional surgery form pediatricpatients. The expressionof TRAIL protein and mRNA were detected respectively by immunohistochemical Streptavidin–perox -idase conjugated method and in situ hybridization techniques.Results: 1.The TRAIL protein positive rates in hemangiomas , vascular malformations and control specimens were 60.66%(37/61), 0% , 0% respectively. There was a significant difference between the three pathologies(P<0.01) .The difference between hemangiomas and vascular malformations and control specimens pathologies was also significant (P<0.01),but there was no statistic significance between vascular malformations and control specimens pathologies(P>0.05). The TRAIL mRNA positive rates in hemangiomas , vascular malformations and control specimens were 77.05(47/61), 0% , 0% respectively. There was a significant difference between the three pathologies(P<0.01). The difference between hemangiomas and vascular malformations and control specimens pathologies was also significant (P<0.01),but there was no statistic significance between vascular malformations and control specimens pathologies(P>0.05).2.The TRAIl protein positive rates in proliferative hemangiomas and involuting hemangiomas were 45.45%(15/33), 78.57%(22/28) respectively. There was a significant difference between the two pathologies(P<0.01) . The TRAIl mRNA positive rates in proliferative hemangiomas and involuting hemangiomas were 66.67%(22/33), 89.29%(25/28) respectively. There was a significant difference between the two pathologies(P<0.01)Conclusion: 1.There was a close relation between the expression of TRAIL protein and mRNA and the various phases of endothelia of hemangioma. It indicated that the biological endothelial cell characteristics of the various stages of hemangioma implicated in concentration of TRAIL protein and mRNA,and also in time of TRAIL protein and mRNA working.2. TRAIL protein and mRNA were expressed by majority of endothelial cells in hemangiomas, especially in involuting hemangiomas, but not in vascular malformations or control group. TRAIL protein and mRNA are important markers of ,involuting hemangiomas,and can provid a basic rational for clinical diagnosis and evaluating therapy resul.3. TRAIL protein and mRNA can accelerate regression of hemangiomas. TRAIL protein and mRNA can cause endothelial apoptosis and tumor dimution. Thereby, this rational should be the important pole for gene target therapies of hemangiomas...